With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
The company reports revenue growth of 26% and PAT growth of 21% YoY
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
